PPAR-γ Pro12Ala genotype and risk of cognitive decline in elders

Neurobiology of Aging

Volumn 29, Issue 1, 2008, Pages 78-83

  Yaffe, K ^a,c   Kanaya, A M ^a,b   Lindquist, K ^a   Hsueh, W C ^b   Cummings, S R ^d   Beamer, B ^e   Newman, A ^f   Rosano, C ^f   Li, R ^g   Harris, T ^h  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^g UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^h NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

Cognitive function; Cognitive impairment; Dementia; Metabolism; PPAR

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

AGE DISTRIBUTION; AGED; ALLELE; ARTICLE; COGNITION; COGNITIVE DEFECT; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEPRESSION; DIABETES MELLITUS; DISEASE ASSOCIATION; DNA POLYMORPHISM; DYSLIPIDEMIA; FEMALE; FOLLOW UP; GENE; GENETIC ASSOCIATION; GENETIC LINKAGE; GENOTYPE; GLUCOSE BLOOD LEVEL; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; MULTIVARIATE ANALYSIS; NEGRO; OBESITY; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA GENE; PRIORITY JOURNAL; RACE; SCORING SYSTEM; SEX RATIO; TASK PERFORMANCE;

AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; AGING; ALANINE; COGNITION DISORDERS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENOTYPE; HUMANS; LONGITUDINAL STUDIES; MALE; MENTAL STATUS SCHEDULE; NEUROPSYCHOLOGICAL TESTS; PPAR GAMMA; PROLINE; RETROSPECTIVE STUDIES; RISK;

EID: 36148993913     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2006.09.010     Document Type: Article

References (29)

1. Altshuler D., Hirschhorn J.N., Klannemark M., Lindgren C.M., Vohl M.C., Nemesh J., et al. The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 26 1 (2000) 76-80
2. Beamer B.A., Yen C.J., Andersen R.E., Muller D., Elahi D., Cheskin L.J., et al. Association of the Pro12Ala variant in the peroxisome proliferator-activated receptor-gamma2 gene with obesity in two Caucasian populations. Diabetes 47 11 (1998) 1806-1808
3. Beres C.A., and Baron A. Improved digit symbol substitution by older women as a result of extended practice. J Gerontol 36 5 (1981) 591-597
4. Bernardo A., Levi G., and Minghetti L. Role of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma) and its natural ligand 15-deoxy-Delta12, 14-prostaglandin J2 in the regulation of microglial functions. Eur J Neurosci 12 7 (2000) 2215-2223
5. Biessels G.J., Staekenborg S., Brunner E., Brayne C., and Scheltens P. Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol 5 1 (2006) 64-74
6. Clement K., Hercberg S., Passinge B., Galan P., Varroud-Vial M., Shuldiner A.R., et al. The Pro115Gln and Pro12Ala PPAR gamma gene mutations in obesity and type 2 diabetes. Int J Obes Relat Metab Disord 24 3 (2000) 391-393
7. Combs C.K., Johnson D.E., Karlo J.C., Cannady S.B., and Landreth G.E. Inflammatory mechanisms in Alzheimer's disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists. J Neurosci 20 2 (2000) 558-567
8. Craft S., and Watson G.S. Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neurol 3 March (3) (2004) 169-178
9. Deeb S.S., Fajas L., Nemoto M., Pihlajamaki J., Mykkanen L., Kuusisto J., et al. A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 20 3 (1998) 284-287
10. Ek J., Urhammer S.A., Sorensen T.I., Andersen T., Auwerx J., and Pedersen O. Homozygosity of the Pro12Ala variant of the peroxisome proliferation-activated receptor-gamma2 (PPAR-gamma2): divergent modulating effects on body mass index in obese and lean Caucasian men. Diabetologia 42 7 (1999) 892-895
11. Fornage M., Jacobs D.R., Steffes M.W., Gross M.D., Bray M.S., and Schreiner P.J. Inverse effects of the PPAR(gamma)2 Pro12Ala polymorphism on measures of adiposity over 15 years in African Americans and Whites. The CARDIA study. Metabolism 54 7 (2005) 910-917
12. Grodstein F., Chen J., Wilson R.S., and Manson J.E. Type 2 diabetes and cognitive function in community-dwelling elderly women. Diabetes Care 24 6 (2001) 1060-1065
13. Heneka M.T., Klockgether T., and Feinstein D.L. Peroxisome proliferator-activated receptor-gamma ligands reduce neuronal inducible nitric oxide synthase expression and cell death in vivo. J Neurosci 20 18 (2000) 6862-6867
14. Hixson J.E., and Vernier D.T. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 31 3 (1990) 545-548
15. Kao W.H., Coresh J., Shuldiner A.R., Boerwinkle E., Bray M.S., and Brancati F.L. Pro12Ala of the peroxisome proliferator-activated receptor-gamma2 gene is associated with lower serum insulin levels in nonobese African Americans: the Atherosclerosis Risk in Communities Study. Diabetes 52 6 (2003) 1568-1572
16. Kielian T., and Drew P.D. Effects of peroxisome proliferator-activated receptor-gamma agonists on central nervous system inflammation. J Neurosci Res 71 3 (2003) 315-325
17. Kuller L.H., Lopez O.L., Newman A., Beauchamp N.J., Burke G., Dulberg C., et al. Risk factors for dementia in the cardiovascular health cognition study. Neuroepidemiology 22 1 (2003) 13-22
18. Lehmann J.M., Moore L.B., Smith-Oliver T.A., Wilkison W.O., Willson T.M., and Kliewer S.A. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 270 22 (1995) 12953-12956
19. Luchsinger J.A., Tang M.X., Shea S., and Mayeux R. Hyperinsulinemia and risk of Alzheimer disease. Neurology 63 7 (2004) 1187-1192
20. Luna-Medina R., Cortes-Canteli M., Alonso M., Santos A., Martinez A., and Perez-Castillo A. Regulation of inflammatory response in neural cells in vitro by thiadiazolidinones derivatives through peroxisome proliferator-activated receptor gamma activation. J Biol Chem 280 22 (2005) 21453-21462
21. Masud S., and Ye S. Effect of the peroxisome proliferator activated receptor-gamma gene Pro12Ala variant on body mass index: a meta-analysis. J Med Genet 40 10 (2003) 773-780
22. McKeigue P.M., Carpenter J.R., Parra E.J., and Shriver M.D. Estimation of admixture and detection of linkage in admixed populations by a Bayesian approach: application to African-American populations. Ann Hum Genet 64 Pt 2 (2000) 171-186
23. Radloff L.S. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas 1 (1977) 385-401
24. Stumvoll M., and Haring H. The peroxisome proliferator-activated receptor-gamma2 Pro12Ala polymorphism. Diabetes 51 8 (2002) 2341-2347
25. Teng E.L., and Chui H.C. The Modified Mini-Mental State (3MS) examination. J Clin Psychiatry 48 8 (1987) 314-318
26. Watson G.S., Cholerton B.A., Reger M.A., Baker L.D., Plymate S.R., Asthana S., et al. Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am J Geriatr Psychiatry 13 11 (2005) 950-958
27. Whitmer R.A., Gunderson E.P., Barrett-Connor E., Quesenberry Jr. C.P., and Yaffe K. Obesity in middle age and future risk of dementia: a 27 year longitudinal population based study. BMJ 330 7504 (2005) 1360
28. Yaffe K., Blackwell T., Kanaya A.M., Davidowitz N., Barrett-Connor E., and Krueger K. Diabetes, impaired fasting glucose, and development of cognitive impairment in older women. Neurology 63 4 (2004) 658-663
29. Yen C.J., Beamer B.A., Negri C., Silver K., Brown K.A., Yarnall D.P., et al. Molecular scanning of the human peroxisome proliferator activated receptor gamma (hPPAR gamma) gene in diabetic Caucasians: identification of a Pro12Ala PPAR gamma 2 missense mutation. Biochem Biophys Res Commun 241 2 (1997) 270-274